Drug-induced immune thrombocytopenic purpura secondary to sunitinib
2008
Case Report of Thrombocytopenia from Sunitinib
Sample size: 1
publication
Evidence: low
Author Information
Author(s): Trinkaus M., Trudeau M., Callum J.
Primary Institution: Sunnybrook Health Sciences Center, University of Toronto
Hypothesis
Can sunitinib cause immune-mediated thrombocytopenia?
Conclusion
The case demonstrates that sunitinib can lead to immune-mediated thrombocytopenia in patients.
Supporting Evidence
- Sunitinib is known to cause thrombocytopenia due to myelosuppression.
- This is the first documented case of immune-mediated thrombocytopenia linked to sunitinib.
- The patient's platelet count improved after stopping sunitinib and receiving treatment.
Takeaway
A woman taking a cancer drug called sunitinib got very low platelet counts, which can cause bleeding. After stopping the drug and getting treatment, her platelet counts went back to normal.
Methodology
Case report detailing the patient's treatment and response to sunitinib.
Limitations
Only one case is reported, limiting generalizability.
Participant Demographics
52-year-old woman with metastatic breast cancer.
Want to read the original?
Access the complete publication on the publisher's website